ILMN:NGS-Illumina Inc. (USD)

EQUITY | Diagnostics & Research | Nasdaq Global Select

Last Closing

USD 136.02

Change

0.00 (0.00)%

Market Cap

USD 19.79B

Volume

0.01B

Analyst Target

USD 347.86
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Illumina Inc provides sequencing-and array-based solutions for genetic analysis. Its products enabled researchers to explore DNA, helping them create the first map of gene variations associated with health, disease, and drug response.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-22 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
IDXX IDEXX Laboratories Inc

+0.90 (+0.22%)

USD 35.79B
NTRA Natera Inc

+0.11 (+0.07%)

USD 22.06B
ICLR ICON PLC

+2.51 (+1.21%)

USD 17.95B
EXAS EXACT Sciences Corporation

-0.47 (-0.79%)

USD 11.56B
MEDP Medpace Holdings Inc

+1.77 (+0.52%)

USD 10.75B
RDNT RadNet Inc

-0.08 (-0.11%)

USD 6.04B
GH Guardant Health Inc

-0.63 (-1.99%)

USD 3.91B
SHC Sotera Health Co

+0.09 (+0.68%)

USD 3.72B
VCYT Veracyte Inc

+0.10 (+0.24%)

USD 3.42B
TWST Twist Bioscience Corp

+0.18 (+0.38%)

USD 2.85B

ETFs Containing ILMN

CURG:LSE VanEck Genomics and Healt.. 6.26 % 0.00 %

-0.01 (-0.09%)

USD 5.35M
CURE:XETRA VanEck Genomics and Healt.. 5.36 % 0.00 %

-0.09 (-0.09%)

N/A
EKG First Trust Nasdaq Lux Di.. 4.16 % 0.00 %

-0.07 (-0.09%)

USD 2.66M
XGES:LSE Xtrackers MSCI Genomic He.. 4.12 % 0.00 %

-0.01 (-0.09%)

N/A
GNOM Global X Genomics & Biote.. 4.09 % 0.00 %

+0.03 (+-0.09%)

USD 0.07B
GNOG:LSE Global X Genomics & Biote.. 4.03 % 0.00 %

+0.01 (+-0.09%)

USD 9.08M
GN0M:XETRA Global X Genomics & Biote.. 3.96 % 0.00 %

-0.04 (-0.09%)

USD 7.05M
GNOM:SW Global X Genomics & Biote.. 3.96 % 0.00 %

N/A

USD 9.83M
XGEN:XETRA Xtrackers MSCI Genomic He.. 3.84 % 0.00 %

-0.14 (-0.09%)

N/A
CDNA:CA CI Bio-Revolution Index E.. 3.33 % 0.00 %

+0.21 (+-0.09%)

CAD 6.05M
2B70:XETRA iShares Nasdaq US Biotech.. 2.40 % 0.00 %

-0.02 (-0.09%)

USD 0.52B
IBBQ Invesco Nasdaq Biotechnol.. 2.35 % 0.00 %

+0.13 (+-0.09%)

USD 0.04B
2B70:F iShares NASDAQ US Biotech.. 2.34 % 0.00 %

N/A

USD 0.52B
2B78:XETRA iShares Healthcare Innova.. 1.89 % 0.00 %

-0.04 (-0.09%)

USD 1.14B
HEAL:SW iShares Healthcare Innova.. 1.87 % 0.00 %

+0.13 (+-0.09%)

N/A
DOCG:LSE L&G Healthcare Breakthrou.. 1.85 % 0.00 %

-3.50 (-0.09%)

USD 0.07B
DOCT:LSE L&G Healthcare Breakthrou.. 1.85 % 0.00 %

+0.04 (+-0.09%)

USD 0.07B
XMLH:F Legal & General Ucits Etf.. 1.84 % 0.00 %

+0.23 (+-0.09%)

USD 0.07B
DOCT:SW L&G Healthcare Breakthrou.. 1.84 % 0.00 %

-0.05 (-0.09%)

USD 0.07B
HTEC Robo Global® Healthcare .. 1.82 % 0.00 %

+0.09 (+-0.09%)

USD 0.05B
BTEC:SW iShares Nasdaq US Biotech.. 1.73 % 0.00 %

+0.10 (+-0.09%)

N/A
ZUH:CA BMO Equal Weight US Healt.. 1.66 % 0.39 %

+0.29 (+-0.09%)

CAD 0.23B
IJJ iShares S&P Mid-Cap 400 V.. 1.51 % 0.25 %

+0.58 (+-0.09%)

USD 8.33B
IVOV Vanguard S&P Mid-Cap 400 .. 1.49 % 0.20 %

-1.19 (-0.09%)

USD 1.16B
SPY4:SW SPDR® S&P 400 US Mid Cap.. 0.73 % 0.00 %

+1.24 (+-0.09%)

USD 4.64B
SPY4:PA SSgA SPDR S&P 400 US Mid .. 0.73 % 0.00 %

-0.96 (-0.09%)

USD 4.93B
SPY4:XETRA SSgA SPDR S&P 400 US Mid .. 0.73 % 0.00 %

-0.78 (-0.09%)

USD 1.99B
MDY SPDR® S&P MIDCAP 400 ETF.. 0.73 % 0.24 %

+1.37 (+-0.09%)

USD 24.18B
IJH iShares Core S&P Mid-Cap .. 0.73 % 0.07 %

+0.16 (+-0.09%)

USD 94.51B
IVOO Vanguard S&P Mid-Cap 400 .. 0.73 % 0.15 %

-0.14 (-0.09%)

USD 2.42B
SPX4:LSE SPDR® S&P 400 US Mid Cap.. 0.62 % 0.00 %

-0.30 (-0.09%)

N/A
MVV ProShares Ultra MidCap400 0.57 % 0.95 %

+0.25 (+-0.09%)

USD 0.14B
MIDU Direxion Daily Mid Cap Bu.. 0.54 % 1.10 %

+0.32 (+-0.09%)

USD 0.09B
UMDD ProShares UltraPro MidCap.. 0.51 % 0.95 %

+0.11 (+-0.09%)

USD 0.04B
EWSP:SW iShares S&P 500 Equal Wei.. 0.23 % 0.00 %

+0.01 (+-0.09%)

USD 3.44B
ALFA 0.00 % 0.65 %

N/A

N/A
BBH VanEck Biotech ETF 0.00 % 0.35 %

-0.25 (-0.09%)

USD 0.42B
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

+0.49 (+-0.09%)

USD 0.08B
BIS ProShares UltraShort Nasd.. 0.00 % 0.95 %

-0.54 (-0.09%)

USD 3.54M
IBB iShares Biotechnology ETF 0.00 % 0.47 %

+0.88 (+-0.09%)

USD 6.91B
IBCE 0.00 % 0.10 %

N/A

N/A
IBDD 0.00 % 0.10 %

N/A

N/A
MDYV SPDR® S&P 400 Mid Cap Va.. 0.00 % 0.15 %

-0.19 (-0.09%)

N/A
PBE Invesco Dynamic Biotechno.. 0.00 % 0.57 %

+0.31 (+-0.09%)

N/A
SPMD SPDR Russell Small Cap Co.. 0.00 % 0.06 %

-0.07 (-0.09%)

USD 12.48B
BTEC 0.00 % 0.42 %

N/A

N/A
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

-0.04 (-0.09%)

N/A
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

N/A
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

-0.03 (-0.09%)

N/A
ZBIO Zenas BioPharma, Inc. Com.. 0.00 % 0.95 %

-0.44 (-0.09%)

N/A
SPY4:LSE SPDR® S&P 400 US Mid Cap.. 0.00 % 0.00 %

-1.02 (-0.09%)

N/A
SPY4:F SSgA SPDR S&P 400 US Mid .. 0.00 % 0.00 %

-0.19 (-0.09%)

N/A
XMLH:XETRA L&G Healthcare Breakthrou.. 0.00 % 0.00 %

-0.07 (-0.09%)

USD 0.07B
GGUE:XETRA UBS Global Gender Equalit.. 0.00 % 0.00 %

-0.10 (-0.09%)

USD 0.23B
BBIG:CA 0.00 % 0.00 %

N/A

N/A
QQEQ:CA Invesco NASDAQ 100 Equal .. 0.00 % 0.00 %

+0.01 (+-0.09%)

CAD 0.01B
2B78:F iShares Healthcare Innova.. 0.00 % 0.00 %

-0.01 (-0.09%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 0.42% 67% D+ 51% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.42% 65% D 47% F
Trailing 12 Months  
Capital Gain -0.12% 69% C- 49% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.12% 67% D+ 46% F
Trailing 5 Years  
Capital Gain -58.32% 45% F 24% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -58.32% 42% F 23% F
Average Annual (5 Year Horizon)  
Capital Gain -15.68% 33% F 15% F
Dividend Return -15.68% 33% F 15% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 34.33% 88% B+ 55% F
Risk Adjusted Return -45.68% 27% F 15% F
Market Capitalization 19.79B 98% N/A 96% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Diagnostics & Research) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 45.90 14% 12%
Price/Book Ratio 10.93 14% 12%
Price / Cash Flow Ratio 48.13 9% 7%
Price/Free Cash Flow Ratio 51.88 10% 8%
Management Effectiveness  
Return on Equity -39.51% 53% 36%
Return on Invested Capital -13.44% 71% 38%
Return on Assets 2.62% 89% 76%
Debt to Equity Ratio 25.92% 64% 56%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector